Drug Shortage Report for ENSPRYNG
Report ID | 227132 |
Drug Identification Number | 02499681 |
Brand name | ENSPRYNG |
Common or Proper name | Satralizumab |
Company Name | HOFFMANN-LA ROCHE LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | SATRALIZUMAB |
Strength(s) | 120MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS |
Packaging size | 120MG Pre-filled Syringe |
ATC code | L04AC |
ATC description | |
Reason for shortage | Requirements related to complying with good manufacturing practices. |
Anticipated start date | 2024-05-15 |
Actual start date | |
Estimated end date | 2024-06-28 |
Actual end date | 2024-05-14 |
Shortage status | Avoided shortage |
Updated date | 2024-05-14 |
Company comments | Resolved before anticipated start date. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 7070 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 5M8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v4 | 2024-05-14 | French | Compare |
v3 | 2024-05-14 | English | Compare |
v2 | 2024-05-06 | French | Compare |
v1 | 2024-05-06 | English | Compare |
Showing 1 to 4 of 4